Price Chart

Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
URL http://www.avadel.com
Investor Relations URL https://investors.avadel.com
HQ State/Province Dublin
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release Mar. 02, 2026 (est.)
Last Earnings Release Nov. 04, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
URL http://www.avadel.com
Investor Relations URL https://investors.avadel.com
HQ State/Province Dublin
Sector Health Care
Industry Pharmaceuticals
Next Earnings Release Mar. 02, 2026 (est.)
Last Earnings Release Nov. 04, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A